Angiotensin Receptor Blockers as Tentative SARS‐CoV‐2 Therapeutics

Drug Development Research - United States
doi 10.1002/ddr.21656
Full Text
Abstract

Available in full text

Categories
Drug Discovery
Date
Authors
Publisher

Wiley

Related search

Human Monoclonal Antibodies Block the Binding of SARS-CoV-2 Spike Protein to Angiotensin Converting Enzyme 2 Receptor

2020English

Human ACE2 Receptor Polymorphisms Predict SARS-CoV-2 Susceptibility

2020English

Angiotensin Receptor Blockers (ARBs)

CMAJ
Medicine
2011English

Development of SARS-COV Therapeutics Using Quaternary Protein Mimetics

English

Analysis of SARS-CoV-2-controlled Autophagy Reveals Spermidine, MK-2206, and Niclosamide as Putative Antiviral Therapeutics

2020English

Differential Antibody Recognition by Novel SARS-CoV-2 and SARS-CoV Spike Protein Receptor Binding Domains: Mechanistic Insights

2020English

SARS-COV-2 and Infectivity

Journal of Medical Virology
VirologyInfectious Diseases
2020English

Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Internal MedicineEndocrinology
2006English

ACE2 Fragment as a Decoy for Novel SARS-Cov-2 Virus

2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy